Assessing risk in pulmonary arterial hypertension: what we know, what we don't Source: Eur Respir J, 50 (2) 1701353; 10.1183/13993003.01353-2017 Year: 2017
Does the application of an algorithm for non-invasive ventilation in chronic obstructive pulmonary disease improve the initiation process, and patient outcomes? Source: Annual Congress 2009 - Riding the tiger: noninvasive ventilation and acute respiratory failure Year: 2009
Optimising pharmacotherapy in patients with pulmonary arterial hypertension and comorbidities, including lung diseases and heart failure: benefits without harm? Source: International Congress 2018 – Integrated care for patients with pulmonary vascular disease, lung diseases and heart failure Year: 2018
Image-based recommendations for the evaluation of pulmonary embolism and arterial hypertension: what? when? how? Source: Virtual Congress 2020 – Image-based guidelines and recommendations in respiratory diseases Year: 2020
Pathophysiology of pulmonary hypertension: what the interested clinician needs to know Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease Year: 2020
Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression? Source: Eur Respir J , 49 (2) 1602345; DOI: 10.1183/13993003.02345-2016 Year: 2017
Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression? Source: Eur Respir J , 49 (2) 1602524; DOI: 10.1183/13993003.02524-2016 Year: 2017
Treatment of pulmonary hypertension due to COPD: can we really hope in better? Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005
Pulmonary hypertension associated with left heart disease: efforts to improve the meaning of haemodynamic phenotypes Source: Eur Respir J, 53 (3) 1802393; 10.1183/13993003.02393-2018 Year: 2019
Pulmonary hypertension associated with left heart disease: efforts to improve the meaning of haemodynamic phenotypes Source: Eur Respir J, 53 (3) 1801894; 10.1183/13993003.01894-2018 Year: 2019
Does aging affect the outcome of comprehensive pulmonary rehabilitation in patients with COPD? Source: Eur Respir J 2003; 22: Suppl. 45, 426s Year: 2003
Measuring health in pulmonary hypertension: emphasising the right end-point? Source: Eur Respir J 2014; 43: 960-962 Year: 2014
The patient tells it! The importance of patient's quality of life perception in pulmonary arterial hypertension risk assessment Source: Eur Respir J, 57 (2) 2004376; 10.1183/13993003.04376-2020 Year: 2021
Dismantling airway disease with the use of new pulmonary function indices Source: Eur Respir Rev, 28 (151) 180122; 10.1183/16000617.0122-2018 Year: 2019
Improving adherence in chronic airways disease: are we doing it wrongly? Source: Breathe, 17 (2) 210022; 10.1183/20734735.0022-2021 Year: 2021
Low-t3 state a crucial biomarker in determining NIV failure and outcome in pulmonary patient? Source: Annual Congress 2011 - Mechanical ventilation and weaning Year: 2011
Does self-management ability improve after pulmonary rehabilitation for chronic obstructive pulmonary disease? Source: International Congress 2019 – Pulmonary rehabilitation for obstructive lung diseases Year: 2019
Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet? Source: Eur Respir Rev 2014; 23: 458-468 Year: 2014
Pulmonary arterial hypertension: the burden of disease and impact on quality of life Source: Eur Respir Rev 2015; 24: 621-629 Year: 2015